Iberdomide in Systemic Lupus Erythematosus In a phase 2 | UPDATES IN MEDICINE
Iberdomide in Systemic Lupus Erythematosus
In a phase 2 trial of iberdomide in patients with moderate-to-severe SLE, a composite response (on the Systemic Lupus Erythematosus Responder Index–4) occurred in 54% of those who received iberdomide (0.45 mg), as compared with 35% in the placebo group, but this between-group difference was not significant at lower doses. Urinary tract and respiratory tract infections and neutropenia occurred.
